Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923967 | 1.00 | BCHE (0.53) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL30317816 | 1.00 | BCHE (0.53) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL24646019 | 0.83 | MAOB (0.50) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL22717056 | 0.83 | KMT2A (0.54) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL28969253 | 0.83 | SMN1; SMN2 (0.51) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL29014138 | 0.83 | SMN1; SMN2 (0.51) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL684282 | 0.82 | MAOB (0.62) | BCHEMAOBKMT2ASMN1; SMN2ALOX5 | |
| SCHEMBL24646025 | 0.81 | SMN1; SMN2 (0.49) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL22724743 | 0.81 | SMN1; SMN2 (0.49) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 | |
| SCHEMBL22717572 | 0.81 | FFAR1 (0.53) | BCHEMAOBKMT2ASMN1; SMN2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-06-12 | — | — | US | disclosed |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | NOVARTIS AG (CH) | 2025-04-29 | — | — | US | disclosed |
| CN-115867545-A | Antiviral 1,3 dioxoindene compounds | 诺华股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188066-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | BCHE 4562/4885MAOB 2196/4885KMT2A 4549/4885 |
| US-20210323947-A1 | ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS | IRF3, EIF2AK2, ZC3HAV1 | BCHE 4562/4885MAOB 2196/4885KMT2A 4549/4885 |
| US-12286423-B2 | Antiviral 1,3-di-oxo-indene compounds | IRF3, EIF2AK2, ZC3HAV1 | BCHE 4562/4885MAOB 2196/4885KMT2A 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.